Literature DB >> 10821370

Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity.

R B Landewé, B E van den Borne, F C Breedveld, B A Dijkmans.   

Abstract

Methotrexate, an antirheumatic drug that may increase serum homocysteine, significantly increases mortality in patients with rheumatoid arthritis and cardiovascular comorbidity.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10821370     DOI： 10.1016/S0140-6736(00)02222-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  29 in total

1.  Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area.

Authors:  J Hamilton; I B McInnes; E A Thomson; D Porter; J A Hunter; R Madhok; H A Capell
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Cardiovascular risk in patients with rheumatoid arthritis: assessment of several traditional risk parameters and a German risk score model.

Authors:  Janina Willers; Andreas Hahn
Journal:  Rheumatol Int       Date:  2011-11-16       Impact factor: 2.631

3.  Methotrexate modulates the kinetics of adenosine in humans in vivo.

Authors:  N P Riksen; P Barrera; P H H van den Broek; P L C M van Riel; P Smits; G A Rongen
Journal:  Ann Rheum Dis       Date:  2005-11-24       Impact factor: 19.103

4.  Use of tissue Doppler and its comparison with other pulse Doppler echocardiography in the evaluation of diastolic functions in patients with active juvenile idiopathic arthritis.

Authors:  Bülent Koca; Tevfik Demir; Özgür Kasapçopur
Journal:  Clin Rheumatol       Date:  2014-08-23       Impact factor: 2.980

Review 5.  Managing cardiovascular risk in patients with chronic inflammatory diseases.

Authors:  Boulos Haraoui; Peter P Liu; Kim A Papp
Journal:  Clin Rheumatol       Date:  2012-01-14       Impact factor: 2.980

Review 6.  Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.

Authors:  Justin C Mason; Peter Libby
Journal:  Eur Heart J       Date:  2014-11-27       Impact factor: 29.983

7.  Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis.

Authors:  R Peltomaa; L Paimela; H Kautiainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

8.  Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells.

Authors:  Carolyn M Summers; Andrea L Hammons; Jasbir Arora; Suhong Zhang; Jeanine Jochems; Ian A Blair; Alexander S Whitehead
Journal:  Eur J Pharmacol       Date:  2014-03-18       Impact factor: 4.432

9.  Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis.

Authors:  Mary Chester M Wasko; Abhijit Dasgupta; Helen Hubert; James F Fries; Michael M Ward
Journal:  Arthritis Rheum       Date:  2013-02

Review 10.  Treatment of inflammatory bowel disease in the elderly: an update.

Authors:  Darrell S Pardi; Edward V Loftus; Michael Camilleri
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.